The Phase 2 open-label trial will study ABX-002 as an adjunctive treatment in 30 adult patients with depressive episodes associated with bipolar I and bipolar II disorder and will utilize ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback